Chemotherapy. 2011;57:363–71.GDC0068 PubMedCrossRef 13. Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31:514–26.PubMedCrossRef
14. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159–69.PubMedCrossRef 15. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic selleckchem solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116:1615–23.PubMedCrossRef KPT-330 molecular weight 16. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis.
Am J Ophthalmol. 1991;112(Suppl):29S–33S.PubMed 17. Proksch JW, Granvil CP, Siou-Mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25:335–44.PubMedCrossRef 18. Comstock TL, Paterno MR, DeCory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and Phase I safety studies. Clin Drug Investig. 2010;30:675–85.PubMedCrossRef 19. Thompson AM. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol. 2007;35:566–77.CrossRef 20. Gunnar H. Acute bacterial conjunctivitis. Acta Ophthalmol.
2008;86:5–17. 21. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis (review). Cochrane Database Syst Rev. 2006;2:CD001211. 22. DeLeon J, Silverstein BE, Allaire C, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for N-acetylglucosamine-1-phosphate transferase 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012;32(5):303–17.PubMedCrossRef 23. Meloni M, Cattaneo G, De Servi B. Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications. Clin Ophthalmol. 2012;6:1433–40.PubMed 24. Whitson JT, Petroll WM. Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents. Adv Ther. 2012;29:874–88.PubMedCrossRef 25. Labbé A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006;22:267–78.PubMedCrossRef 26. Sarkar J, Chaudhary S, Namavari A, et al. Corneal toxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53:1792–802.PubMedCrossRef 27. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microb Rev. 1999;12:147–79.